Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20357247 | 1.00 | HCAR2 (0.45) | HCAR2ATMTSHRALDH1A1CYP3A4 | |
| SCHEMBL25316316 | 1.00 | HCAR2 (0.45) | HCAR2ATMTSHRALDH1A1CYP3A4 | |
| SCHEMBL27197554 | 1.00 | HCAR2 (0.45) | HCAR2ATMTSHRALDH1A1CYP3A4 | |
| SCHEMBL25317040 | 1.00 | HCAR2 (0.45) | HCAR2ATMTSHRALDH1A1CYP3A4 | |
| SCHEMBL1132928 | 0.98 | ATM (0.46) | HCAR2ATMTSHRALDH1A1CYP3A4 | |
| SCHEMBL37109 | 0.94 | ATM (0.47) | HCAR2ATMTSHRALDH1A1CYP3A4 | |
| SCHEMBL845291 | 0.87 | ATM (0.41) | HCAR2ATMTSHRMAPTRAB9A | |
| SCHEMBL4264196 | 0.87 | ATM (0.41) | HCAR2ATMTSHRMAPTRAB9A | |
| SCHEMBL22367589 | 0.86 | HCAR2 (0.44) | HCAR2ATMTSHRALDH1A1CYP3A4 | |
| SCHEMBL21802972 | 0.86 | HCAR2 (0.44) | HCAR2ATMTSHRALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024024370-A1 | PHOTOCURABLE COMPOSITION, CURED PRODUCT OF SAME, AND COATED ARTICLE | 信越化学工業株式会社 | 2024-02-01 | — | — | WO | disclosed |
| US-20230303404-A1 | NANOPARTICLES, DISPERSION OF NANOPARTICLES, AND PRODUCTION METHOD OF NANOPARTICLES | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-09-28 | — | — | US | disclosed |
| US-20230242692-A1 | COMPOSITION AND CURED PRODUCT | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303404-A1 | NANOPARTICLES, DISPERSION OF NANOPARTICLES, AND PRODUCTION METHOD OF NANOPARTICLES | CD63, NIBAN2, ZRANB2 | HCAR2 4705/4885ATM 3034/4885TSHR 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.